The large volume wearable injectors market is projected to grow at an annualized rate of ~35%{RootsAnalysis}
Roots Analysis has done a detailed study on Large Volume Wearable Injectors Market (5th Edition), 2020-2030:Focus on Bolus, Basal and Continuous Delivery Devices.”, covering key aspects of the industry’s current trendsand identifying potential future growth opportunities.
To order this 540+ pagereport, which features 175+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors/238.html
Key Market Insights
§ More than 40 largevolume wearable injectors are presently available / under development for theadministration of drugs, beyond insulin, including 15+ drug device combinations
§ Companies focused ondeveloping devices for the delivery of insulin have already established strongbrand positions in this domain, with 30+ devices currently under development oravailable
§ More than 200biologics / small molecule drugs were identified as likely products to bedeveloped in combination with large volume wearable injectors
§ The rising interest in this field is reflected in the number ofpartnerships (90+) inked between 2015
and 2020 (tillJune), involving both international and indigenous stakeholders, across theworld
§ An evaluation of 50+stakeholders engaged in the development of large volume wearable injectorsrevealed the existence of several likely acquisition targets, across differentgeographical regions
§ The market, for the large volume wearable injectors for the delivery ofnon-insulin drugs is projected to beworth USD 600 million; owing to the increasing incidence of chronic clinicalconditions and growing pipeline of therapeutic interventions to treat suchdiseases
§ The large volumewearable injectors market for insulin is anticipated to be worth over USD 2.7billion by 2030; the anticipated opportunity is likely to be distributed acrossvarious different device types, therapeutic areas and geographies
For more information, please visit https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html
Table of Contents
1. PREFACE
1.1. Scope ofthe Report
1.2. Research Methodology
1.3. ChapterOutlines
2. EXECUTIVESUMMARY
3. INTRODUCTION
3.1. ChapterOverview
3.2. An Overviewof Drug Delivery Devices
3.3. ConventionalParenteral Drug Delivery
3.3.1 NeedlestickInjuries
3.4. Emergenceof Self-Administration Devices
3.4.1. DrivingFactors
3.5. AvailableSelf-Injection Devices
3.5.1. PrefilledSyringes
3.5.2. Pen-Injectors
3.5.3. Needle-FreeInjectors
3.5.4. Autoinjectors
3.5.5. Large VolumeWearable Injectors
3.6. RegulatoryConsiderations
3.6.1. MedicalDevices
3.6.2. Drug DeviceCombination Products
3.7. FuturePerspectives of Self-Injection Systems
4. LARGEVOLUME WEARABLE INJECTORS: CURRENT MARKET LANDSCAPE
4.1. ChapterOverview
4.2. LargeVolume Wearable Injectors: Overall Market Landscape
4.2.1. Large VolumeWearable Injectors for Non-Insulin Drugs: Market Landscape
4.2.1.1. Analysis byStage of Development
4.2.1.2. Analysis byType of Device
4.2.1.3. Analysis byType of Dose
4.2.1.4. Analysis byRoute of Administration
4.2.1.5. Analysis byMode of Injection
4.2.1.6. Analysis byVolume / Storage Capacity
4.2.1.7. Analysis byActuation Mechanism
4.2.1.8. Analysis byUsability
4.2.1.9. Analysis byAvailability of Prefilled Drug Reservoir
4.2.1.10. Analysis by Availability of Connectivity
4.2.2. Large VolumeDrug Device Combinations: Market Landscape
4.2.2.1. Analysis byStage of Development
4.2.2.2. Analysis byType of Device
4.2.2.3. Analysis byDrug Compatibility
4.2.2.4. Analysis byType of Dose
4.2.2.5. Analysis byRoute of Administration
4.2.2.6. Analysis byMode of Injection
4.2.2.7. Analysis byTherapeutic Area
4.2.2.8. Analysis byVolume / Storage Capacity
4.2.2.9. Analysis byUsability
4.2.3. Large VolumeWearable Injectors for Non-Insulin Drugs: Analysis of Developers (Devices and Drug Device Combinations)
4.2.3.1. Analysis byYear of Establishment
4.2.3.2. Analysis byCompany Size
4.2.3.3. Analysis byGeography
4.2.4. Large VolumeWearable Injectors for Insulin: Market Landscape
4.2.4.1. Analysis byStage of Development
4.2.4.2. Analysis byType of Device
4.2.4.3. Analysis byVolume / Storage Capacity
4.2.4.4. Analysis byUsability
4.2.4.5. Analysis byAvailability of Prefilled Insulin Cartridges
4.2.4.6. Analysis byAvailability of CGM / BGM System
4.2.4.7. Analysis byAvailability of Automated Insulin Delivery (AID) Feature
4.2.4.8. Analysis byAvailability of Connectivity
4.2.4.9. Analysis byType of Remote Control Features
4.2.5. LargeVolume Wearable Injectors for Insulin: Analysis of Developers
4.2.5.1. Analysis byYear of Establishment
4.2.5.2. Analysis byCompany Size
4.2.5.3. Analysis byGeography
5. PRODUCTCOMPETITIVENESS ANALYSIS
5.1. ChapterOverview
5.2. Methodology
5.3. Assumptions/ Key Parameters
5.4. ProductCompetitiveness Analysis
5.4.1. Large VolumeWearable Injectors for Non-Insulin Drugs
5.4.2. Large VolumeDrug Device Combinations
5.4.3. Large VolumeWearable Injectors for Insulin
6. LARGEVOLUME WEARABLE INJECTORS: KEY PLAYERS
6.1. Chapter Overview
6.2. LargeVolume Wearable Injectors for Non-Insulin Drugs: Key Players
6.2.1. BectonDickinson
6.2.1.1. CompanySnapshot
6.2.1.2. FinancialInformation
6.2.1.3. ProductPortfolio
6.2.1.4. RecentDevelopments and Future Outlook
6.2.2. Bespak
6.2.2.1. CompanySnapshot
6.2.2.2. FinancialInformation
6.2.2.3. ProductPortfolio
6.2.2.4. RecentDevelopments and Future Outlook
6.2.3. EnableInjections
6.2.3.1. CompanySnapshot
6.2.3.2. ProductPortfolio
6.2.3.3. RecentDevelopments and Future Outlook
6.2.4. Insulet
6.2.4.1. CompanySnapshot
6.2.4.2. FinancialInformation
6.2.4.3. ProductPortfolio
6.2.4.4. RecentDevelopments and Future Outlook
6.2.5. Roche
6.2.5.1. CompanySnapshot
6.2.5.2. FinancialInformation
6.2.5.3. ProductPortfolio
6.2.5.4. RecentDevelopments and Future Outlook
6.2.6. SensileMedical
6.2.6.1. CompanySnapshot
6.2.6.2. ProductPortfolio
6.2.6.3. RecentDevelopments and Future Outlook
6.2.7. Sonceboz
6.2.7.1. CompanySnapshot
6.2.7.2. ProductPortfolio
6.2.7.3. RecentDevelopments and Future Outlook
6.2.8. SteadyMedTherapeutics
6.2.8.1. CompanySnapshot
6.2.8.2. ProductPortfolio
6.2.8.3. RecentDevelopments and Future Outlook
6.2.9. Weibel CDS
6.2.9.1. CompanySnapshot
6.2.9.2. ProductPortfolio
6.2.9.3. RecentDevelopments and Future Outlook
6.2.10. WestPharmaceutical Services
6.2.10.1. Company Snapshot
6.2.10.2. Financial Information
6.2.10.3. Product Portfolio
6.2.10.4. Recent Developments and Future Outlook
6.3. LargeVolume Wearable Injectors for Insulin: Key Players
6.3.1. CeQur
6.3.1.1. CompanySnapshot
6.3.1.2. ProductPortfolio
6.3.1.3. RecentDevelopments and Future Outlook
6.3.2. Debiotech
6.3.2.1. CompanySnapshot
6.3.2.2. ProductPortfolio
6.3.2.3. RecentDevelopments and Future Outlook
6.3.3. Eli Lilly
6.3.3.1. CompanySnapshot
6.3.3.2. FinancialInformation
6.3.3.3. ProductPortfolio
6.3.3.4. RecentDevelopments and Future Outlook
6.3.4. Medtronic
6.3.4.1. CompanySnapshot
6.3.4.2. FinancialInformation
6.3.4.3. ProductPortfolio
6.3.4.4. RecentDevelopments and Future Outlook
6.3.5. PharmaSens
6.3.5.1. CompanySnapshot
6.3.5.2. ProductPortfolio
6.3.5.3. RecentDevelopments and Future Outlook
6.3.6. SOOILDevelopment
6.3.6.1. CompanySnapshot
6.3.6.2. Product Portfolio
6.3.6.3. RecentDevelopments and Future Outlook
6.3.7. TandemDiabetes Care
6.3.7.1. CompanySnapshot
6.3.7.2. FinancialInformation
6.3.7.3. ProductPortfolio
6.3.7.4. RecentDevelopments and Future Outlook
7. DRUG-DEVICECOMBINATIONS: TABULATED PROFILES
7.1. ChapterOverview
7.2. Apomorphine /D-mine® Pump
7.3. Apomorphine /ND0701
7.4. Bupivacaine /SMT-301
7.5. Ceftriaxone /sc2Wear® Infusor
7.6. Furosemide / 3mL Micropump
7.7. Furosemide /FUROSCIX® On-body Infusor
7.8. Herceptin® / SingleUse Injector
7.9. Ketorolac /SMT-201
7.10. Levodopa andCarbidopa / ND0612 and ND0901
7.11. Lutrepulse /The LUTREPULSE® System
7.12. Neulasta® /Neulasta OnPro™ On-body Injector
7.13. Repatha® /Pushtronex® System
7.14. Treprostinil /Trevyent®
8. PARTNERSHIPSAND COLLABORATIONS
8.1. ChapterOverview
8.2. PartnershipModels
8.3. LargeVolume Wearable Injectors: List of Partnerships and Collaborations
8.3.1. Analysis byYear of Partnership
8.3.2. Analysis byType of Partnership
8.3.3. Analysis by Typeof Device
8.3.4. Analysis byYear of Partnership and Type of Partner
8.3.5. Most ActivePlayers: Analysis by Number of Partnerships
8.3.6. RegionalAnalysis
8.3.7. Intercontinentaland Intracontinental Agreements
9. KEYACQUISITION TARGETS
9.1. ChapterOverview
9.2. Scope andMethodology
9.3. ScoringCriteria and Key Assumptions
9.4. PotentialStrategic Acquisition Targets for Non-Insulin Drug Delivery Players
9.5. PotentialStrategic Acquisition Targets for Insulin Drug Delivery Players
9.6. ConcludingRemarks
10. PATENTANALYSIS
10.1. ChapterOverview
10.2. Scope andMethodology
10.3. Large VolumeWearable Injectors: Patent Analysis
10.3.1. Analysis byPublication Year
10.3.2. Analysis byIssuing Authority / Patent Offices Involved
10.3.3. Analysis byCPC Symbols
10.3.4. EmergingFocus Areas
10.3.5. Analysis byType of Organization
10.3.6. LeadingPlayers: Analysis by Number of Patents
10.4. Large VolumeWearable Injectors: Patent Benchmarking Analysis
10.4.1. Analysis byPatent Characteristics
10.5. Large VolumeWearable Injectors: Patent Valuation Analysis
11. LARGEVOLUME WEARABLE INJECTORS: LIKELY DRUG CANDIDATES
11.1. ChapterOverview
11.2. MarketedDrugs
11.2.1. Most LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.2.2. LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.2.3. Less LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.2.4. UnlikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3. ClinicalDrug Candidates
11.3.1. Biologics
11.3.1.1. Most LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.1.2. LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.1.3. Less LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.1.4. UnlikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.2. SmallMolecules
11.3.2.1. Most LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.2.2. LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.2.3. Less LikelyCandidates for Delivery via Large Volume Wearable Injectors
11.3.2.4. UnlikelyCandidates for Delivery via Large Volume Wearable Injectors
12. EMERGINGTRENDS ON SOCIAL MEDIA
12.1. ChapterOverview
12.2. Large VolumeWearable Injectors: Trends on Twitter
12.2.1. HistoricalTrend in Volume of Tweets
12.2.2. TrendingWords / Phrases Related to Large Volume Wearable Injectors
12.2.3. MostInfluential Authors
12.2.4. PopularPlayers on Twitter
12.2.4.1. Roche (ACCU-CHEK®Solo Micropump System)
12.2.4.2. Insulet(Omnipod®)
12.2.4.3. Medtronic(MiniMed® Wearable Injectors)
12.2.4.4. Comparisonof Popular Players Based on Number of Tweets
12.3. ConcludingRemarks
13. CLINICALTRIAL ANALYSIS
13.1. ChapterOverview
13.2. Scope andMethodology
13.3. Large VolumeWearable Injectors: Clinical Trial Analysis
13.3.1. Analysis byTrial Registration Year
13.3.2. Analysis byTrial Phase
13.3.3. Analysis byTrial Recruitment Status
13.3.4. Analysis byTrial Registration and Number of Patients Enrolled
13.3.5. Analysis byStudy Design
13.3.6. Analysis byType of Sponsor / Collaborator
13.3.7. LeadingPlayers: Analysis by Number of Registered Trials
13.3.8. Word Cloud:Key Focus Areas
13.3.9. Analysis byTherapeutic Area
13.3.10. PopularDrug Device Combinations: Analysis by Number of Registered Trials
13.3.11. GeographicalAnalysis by Number of Registered Trials
13.3.12. GeographicalAnalysis by Patients Enrolled
13.3.13. Analysis byClinical Endpoints
14. CASE STUDY:ROLE OF CMOs IN DEVICE DEVELOPMENT SUPPLY CHAIN
14.1. ChapterOverview
14.2. DeviceDevelopment Supply Chain
14.3. Significanceof CMOs in the Drug Delivery Device Development Process
14.4. List ofContract Manufacturing Organizations
14.4.1. Contract Manufacturers:Geographical Distribution and Services Offered
15. REGULATORYAND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
15.1. ChapterOverview
15.2. GeneralRegulatory and Reimbursement Guidelines for Medical Devices
15.3. Regulatoryand Reimbursement Landscape in North America
15.3.1. The USScenario
15.3.2. The Canadian Scenario
15.3.3. The Mexican Scenario
15.4. Regulatoryand Reimbursement Landscape in Europe
15.4.1. OverallScenario
15.4.1.1. OverallRegulatory Authority
15.4.1.2. OverallReview / Approval Process
15.4.2. The UKScenario
15.4.3. The FrenchScenario
15.4.4. The GermanScenario
15.4.5. The ItalianScenario
15.4.6. The SpanishScenario
15.5. Regulatoryand Reimbursement Landscape in Asia-Pacific and Rest of the World
15.5.1. TheAustralian Scenario
15.5.2. TheBrazilian Scenario
15.5.3. The ChineseScenario
15.5.4. The IndianScenario
15.5.5. The IsraeliScenario
15.5.6. TheJapanese Scenario
15.5.7. The NewZealand Scenario
15.5.8. TheSingaporean Scenario
15.5.9. The SouthKorea Scenario
15.5.10. The SouthAfrican Scenario
15.5.11. TheTaiwanese Scenario
15.5.12. TheThailand Scenario
15.6. Comparisonof Regional Regulatory Environment
15.7. ConcludingRemarks
16. MARKETSIZING AND OPPORTUNITY ANALYSIS
16.1. ChapterOverview
16.2. ForecastMethodology and Key Assumptions
16.3. Global LargeVolume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (By Value)
16.3.1. Global LargeVolume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type ofDevice, 2020-2030 (By Value)
16.3.2 Global LargeVolume Wearable Injectors Market for Non-Insulin Drugs: Distribution byUsability, 2020-2030 (By Value)
16.3.3 Global LargeVolume Wearable Injectors Market for Non-Insulin Drugs: Distribution by TherapeuticArea, 2020-2030 (By Value)
16.4 Large VolumeWearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (ByValue)
16.4.1 Large VolumeWearable Injectors Market for Non-Insulin Drugs in North America: Distributionby Type of Device, 2020-2030 (By Value)
16.4.2 Large VolumeWearable Injectors Market for Non-Insulin Drugs in North America: Distributionby Usability, 2020-2030 (By Value)
16.4.3 Large VolumeWearable Injectors Market for Non-Insulin Drugs in North America: Distributionby Therapeutic Area, 2020-2030 (By Value)
16.5 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (By Value)
16.5.1 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Typeof Device, 2020-2030 (By Value)
16.5.2 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Europe: Distribution byUsability, 2020-2030 (By Value)
16.5.3 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Europe: Distribution byTherapeutic Area, 2020-2030 (By Value)
16.6 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (ByValue)
16.6.1 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distributionby Type of Device, 2020-2030 (By Value)
16.6.2 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distributionby Usability, 2020-2030 (By Value)
16.6.3 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distributionby Therapeutic Area, 2020-2030 (By Value)
16.7. Global LargeVolume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (By Volume)
16.7.1. Global LargeVolume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type ofDevice, 2020-2030 (By Volume)
16.7.2 Global LargeVolume Wearable Injectors Market for Non-Insulin Drugs: Distribution byUsability, 2020-2030 (By Volume)
16.7.3 Global LargeVolume Wearable Injectors Market for Non-Insulin Drugs: Distribution byTherapeutic Area, 2020-2030 (By Volume)
16.8 Large VolumeWearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (ByVolume)
16.8.1 Large VolumeWearable Injectors Market for Non-Insulin Drugs in North America: Distributionby Type of Device, 2020-2030 (By Volume)
16.8.2 Large VolumeWearable Injectors Market for Non-Insulin Drugs in North America: Distributionby Usability, 2020-2030 (By Volume)
16.8.3 Large VolumeWearable Injectors Market for Non-Insulin Drugs in North America: Distributionby Therapeutic Area, 2020-2030 (By Volume)
16.9 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (ByVolume)
16.9.1 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Typeof Device, 2020-2030 (By Volume)
16.9.2 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Europe: Distribution byUsability, 2020-2030 (By Volume)
16.9.3 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Europe: Distribution byTherapeutic Area, 2020-2030 (By Volume)
16.10 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (ByValue)
16.10.1 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distributionby Type of Device, 2020-2030 (By Value)
16.10.2 Large VolumeWearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distributionby Usability, 2020-2030 (By Value)
16.10.3 LargeVolume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific:Distribution by Therapeutic Area, 2020-2030 (By Value)
16.11. Global LargeVolume Wearable Injectors Market for Insulin, 2020-2030
16.11.1 Global LargeVolume Wearable Injectors Market for Insulin: Distribution by Type of Device,2020-2030
16.11.2 Global LargeVolume Wearable Injectors Market for Insulin: Distribution by Usability,2020-2030
16.12 Large VolumeWearable Injectors Market for Insulin in North America, 2020-2030
16.12.1 Large VolumeWearable Injectors Market for Insulin in North America: Distribution by Type ofDevice, 2020-2030
16.12.2 Large VolumeWearable Injectors Market for Insulin in North America: Distribution byUsability, 2020-2030
16.13 Large VolumeWearable Injectors Market for Insulin in Europe, 2020-2030
16.13.1 Large VolumeWearable Injectors Market for Insulin in Europe: Distribution by Type ofDevice, 2020-2030
16.13.2 Large VolumeWearable Injectors Market for Insulin in Europe: Distribution by Usability,2020-2030
16.14 Large VolumeWearable Injectors Market for Insulin in Asia Pacific, 2020-2030
16.14.1 Large VolumeWearable Injectors Market for Insulin in Asia Pacific: Distribution by Type ofDevice, 2020-2030
16.14.2 Large VolumeWearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability,2020-2030
17. SWOTANALYSIS
17.1. ChapterOverview
17.2. SWOTAnalysis
17.2.1. Strengths
17.2.2. Weaknesses
17.2.3. Opportunities
17.2.4. Threats
17.3. Large VolumeWearable Injectors: Future Growth Opportunities
17.3.1. Rising Focuson Self-Administration of Drugs
17.3.2. Possibilityof Integration with Mobile Applications
17.3.3. PotentialLife Cycle Management Tool
17.3.4. PotentialUsability for Multiple Therapeutic Areas
18. EXECUTIVEINSIGHTS
18.1. ChapterOverview
18.2. Subcuject
18.2.1. CompanySnapshot
18.2.2. InterviewTranscript: Jesper Roested, Chief Executive Officer (Q2 2020)
18.3. SorrelMedical
18.3.1. CompanySnapshot
18.3.2. InterviewTranscript: Mindy Katz, Director of Product (Q2 2020)
18.4. Medipacs
18.4.1. CompanySnapshot
18.4.2. InterviewTranscript: Mark Banister, Chief Executive Officer (Q3 2016)
18.5. ElcamMedical
18.5.1. CompanySnapshot
18.5.2. InterviewTranscript: Menachem Zucker, Vice President and Chief Scientist (Q3 2016)
18.6. WestPharmaceutical Services
18.6.1. CompanySnapshot
18.6.2. InterviewTranscript: Graham Reynolds, Vice President and General Manager, Biologics (Q32016)
18.7. EnableInjections
18.7.1. CompanySnapshot
18.7.2. InterviewTranscript: Michael Hooven, Chief Executive Officer (Q3 2014)
18.8. scPharmaceuticals
18.8.1. CompanySnapshot
18.8.2. Interview Transcript: Pieter Muntendam, formerPresident and Chief Executive Officer (Q3 2014)
19. APPENDIX 1:TABULATED DATA
20. APPENDIX 2:LIST OF COMPANIES AND ORGANIZATIONS
Gaurav Chaudhary
+1 (415) 800 3415
